Invited Panel Presentation of Dr. Diana Zuckerman at FDA OMUFA Meeting

We were invited to present at the FDA OMUFA November 2024 meeting on the OTC user fee program commitment letter. We appreciate the priority given to safety OMORs (Monograph revisions) but are concerned that the funding is focused on speed of reviews and industry access to FDA staff, not to pay for staff to conduct FDA safety reviews of OTC medications being sold for years without evidence of safety and effectiveness. OTC products will be safer if consumers and public health experts are present when negotiations take place.

The post Invited Panel Presentation of Dr. Diana Zuckerman at FDA OMUFA Meeting first appeared on National Center for Health Research.

The post Invited Panel Presentation of Dr. Diana Zuckerman at FDA OMUFA Meeting appeared first on National Center for Health Research.